ABSTRACT:
Background: Secondary infections in hospitalized, severely ill Covid-19 patients are common. Notably, fungal infections have been reported to occur 10 times higher than usual. Rhino Orbital Mucormycosis, is a rare condition affecting the nose, paranasal sinuses, orbit, and brain. We share clinical insights from 21 cases, the predisposing factors, clinical presentation, management, and prognosis of this infection. Methods: A retrospective study reviewed the records of 21 patients diagnosed with rhino-orbital mucormycosis. Diabetes and post-COVID status were prevalent risk factors with facial swelling and facial pain were most frequently reported signs and symptoms. The treatment protocol for all patients consisted of intravenous Amphotericin administered both before and after surgery, along with surgical debridement. Conclusion: Early diagnosis of the disease extent are essential for effective management. Advanced treatments have significantly improved survival rates. To minimize the risk of Mucormycosis in COVID-19 patients, it is advised to keep blood glucose levels under control and to use steroids and antibiotics judiciously.